LAUSR

2054 www.ccmjournal.org December 2018 • Volume 46 • Number 12 REFERENCES 1. Altman DG: The scandal of poor medical research. BMJ 1994; 308:283–284 2. Kyriacou DN: The enduring evolution of the p value. JAMA 2016; 315:1113–1115 3. Goodman S: A dirty dozen: Twelve p-value misconceptions. Semin Hematol 2008; 45:135–140 4. Schulz KF, Altman DG, Moher D; CONSORT Group: CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340:c332 5. Wasserstein RL, Lazar NA: The ASA’s statement on p-values: Context, process, and purpose. Am Stat 2016; 70:129–133 6. Chavalarias D, Wallach JD, Li AH, et al: Evolution of reporting p values in the biomedical literature, 1990–2015. JAMA 2016; 315:1141–1148 7. Gates S: New England Journal of Medicine for the last time. Reducing Uncertainty: clinical trials and statistics, mostly. 2018. Available at: https://simongates.com/2018/08/01/new-england-journal-of-medicinefor-the-last-time/. Accessed September 5, 2018 8. The New England Journal of Medicine: New Manuscripts: Guidelines for Statistical Methods. 2018. Available at: https://www.nejm.org/ author-center/new-manuscripts. Accessed August 4, 2018 9. Ioannidis JPA: The proposal to lower p value thresholds to.005. JAMA 2018; 319:1429–1430 10. Blume JD, D’Agostino McGowan L, Dupont WD, et al: Secondgeneration p-values: Improved rigor, reproducibility, & transparency in statistical analyses. PLoS One 2018; 13:e0188299 11. Begley CG, Ellis LM: Drug development: Raise standards for preclinical cancer research. Nature 2012; 483:531–533 12. McCullough JPA, Lipman J, Presneill JJ: The Statistical Curriculum Within Randomized Controlled Trials in Critical Illness. Crit Care Med 2018; 46:1985–1990 13. Windish DM, Huot SJ, Green ML: Medicine residents’ understanding of the biostatistics and results in the medical literature. JAMA 2007; 298:1010–1022 14. Lewis RJ, Angus DC, Laterre PF, et al: Rationale and design of an adaptive phase 2b/3 clinical trial of selepressin for adults in septic shock. Selepressin evaluation programme for sepsis-induced shockadaptive clinical trial. Ann Am Thorac Soc 2018; 15:250–257 15. REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia, 2016. Available at: https:// clinicaltrials.gov/ct2/show/NCT02735707. Accessed August 4, 2018